Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect of Nurix Therapeutics, Inc. from 30 Nov 2019 to 28 Feb 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Summary
Nurix Therapeutics, Inc. quarterly and annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect in USD history and change rate from 30 Nov 2019 to 28 Feb 2025.
  • Nurix Therapeutics, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for the quarter ending 28 Feb 2025 was $34,081,000, a 608% decline year-over-year.
  • Nurix Therapeutics, Inc. annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2024 was $55,370,000.
  • Nurix Therapeutics, Inc. annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2023 was $9,847,000, a 36% increase from 2022.
  • Nurix Therapeutics, Inc. annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2022 was $15,417,000, a 60% increase from 2021.
Source SEC data
View on sec.gov
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Quarterly (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, YoY Quarterly Change (%)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Annual (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, YoY Annual Change (%)

Nurix Therapeutics, Inc. Quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $34,081,000 -$29,267,000 -608% 01 Dec 2024 28 Feb 2025 10-Q 08 Apr 2025 2025 Q1
Q1 2024 $4,814,000 +$26,089,000 +84% 01 Dec 2023 29 Feb 2024 10-Q 08 Apr 2025 2025 Q1
Q1 2023 $30,903,000 -$29,792,000 -2682% 01 Dec 2022 28 Feb 2023 10-Q 10 Apr 2024 2024 Q1
Q1 2022 $1,111,000 -$8,136,000 -116% 01 Dec 2021 28 Feb 2022 10-Q 13 Apr 2023 2023 Q1
Q1 2021 $7,025,000 -$14,569,000 -67% 01 Dec 2020 28 Feb 2021 10-Q 08 Apr 2022 2022 Q1
Q1 2020 $21,594,000 01 Dec 2019 29 Feb 2020 10-Q 13 Apr 2021 2021 Q1

Nurix Therapeutics, Inc. Annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $55,370,000 +$65,217,000 01 Dec 2023 30 Nov 2024 10-K 28 Jan 2025 2024 FY
2023 $9,847,000 +$5,570,000 +36% 01 Dec 2022 30 Nov 2023 10-K 28 Jan 2025 2024 FY
2022 $15,417,000 +$23,317,000 +60% 01 Dec 2021 30 Nov 2022 10-K 28 Jan 2025 2024 FY
2021 $38,734,000 -$123,274,000 -146% 01 Dec 2020 30 Nov 2021 10-K 09 Feb 2023 2022 FY
2020 $84,540,000 +$75,315,000 +816% 01 Dec 2019 30 Nov 2020 10-K 28 Jan 2022 2021 FY
2019 $9,225,000 01 Dec 2018 30 Nov 2019 10-K 28 Jan 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.